Zai Lab
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · China · 1K - 5K Employees
View Company Info for Free
Overview
Headquarters
Jinchuang Plaza 4560 Jinke Rd 4/f Bldg 1...Phone Number
+86 2161632588Website
www.zailaboratory.comRevenue
$427.8 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
3
3
1
1
1
1
About Zai Lab
Zai Lab functions as a bio-pharmaceutical and drug discovery company with a focus in oncology and autoimmune diseases. The company was established in 2014 and is headquartered out of Shanghai, China.Explore more
Zai Lab Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Zai Lab your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Zai Lab recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Zai Lab
Product Launch: Get notified when Zai Lab launches new products
Funding: Get notified immidiatlly once Zai Lab has new funding data
Check out if Zai Lab is spiking on competitors!
Check if Zai Lab has recently received funding, and reach out quickly before it becomes old news!
Click to see if Zai Lab had a recent Job posting/layoffs
Zai Lab, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Company Profile Activity
Activity Insights
Zai Lab is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Zai Lab is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Zai Lab.
Zai Lab financials insights
Gather financial insights about Zai Lab, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Series A
$30M
2016
Series B
$100M
2017
Series C
$30M
Stock Offering
$150M
2020
Share Placement
$261.3M
Stock Offering
$825M
Zai Lab Tech Stack
A closer look at the technologies used by Zai Lab
See more technologies
Most Recent Scoops
Person-Based
Hiring Plans
Zai Lab has more open roles in Operations than it has had at any time in the past 12 months.
Hiring Plans
Person-Based
Medical Research, Pharmaceuticals
Person-Based
Earnings, Finance
Person-Based
Earnings, Financial Reporting, Finance
Zai Lab News & Media
Zai Lab Limited (ZLAB) Discusses Intracranial Activity of a New Therapy in Small Cell Lung Cancer With Brain Metastases Transcript
Zai Lab Limited (ZLAB) Discusses Intracranial Activity of a New Therapy in Small Cell Lung Cancer With Brain Metastases April 20, 2026 8:30 AM EDTCompany...Boehringer Ingelheim and Zai Lab announce Collaboration on DLL3‑targeting T‑Cell Engager and ADC Combination in Small Cell Lung Cancer and Other Neuroendocrine Carcinomas
Ingelheim, Germany and Shanghai, China/Cambridge, Mass. – 15 April, 2026 – Boehringer Ingelheim and Zai Lab (NASDAQ: ZLAB; HKEX: 9688) today announced a clinical collaboration focused on pioneering a dual DLL3-targeting combination. The Phase Ib/II study will assess the safety, tolerability, and initial clinical activity of combining obrixtamig, Boehringer Ingelheim’s DLL3/CD3 T-cell engager, with zocilurtatug pelitecan (zoci; formerly ZL‑1310), Zai Lab’s DLL3-targeting ADC. The study will enrolJPMorgan Cuts PT on Zai Lab Limited (ZLAB) to $32 From $39 – Here’s Why
Zai Lab Limited (NASDAQ:ZLAB) is one of the best high growth healthcare stocks to buy now. JPMorgan cut the price target on Zai Lab Limited (NASDAQ:ZLAB) to $32 from $39 on March 18, reiterating an Overweight rating on the shares. The rating update came after the firm updated models in the smid-cap biotechnology space. In its fiscal […]Zai Lab Q4 Earnings Call Highlights
Zai Lab (NASDAQ:ZLAB) executives used the company’s fourth-quarter and full-year 2025 earnings call to outline progress toward a more globally oriented pipeline while emphasizing that the company’s China commercial business remains a key source of stability and funding for research and development.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Zai Lab
Sign Up For FreeTo access detailed company insights
Zai Lab functions as a bio-pharmaceutical and drug discovery company with a focus in oncology and autoimmune diseases. The company was established in 2014 and is headquartered out of Shanghai, China.... Read More
